Eribulin in non-small cell lung cancer

challenges and potential strategies

Umang Swami, Umang Shah, Sanjay Goel

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Eribulin is a non-taxane, macrocyclic, synthetic, ketone analog of halichondrin B with a microtubule inhibitory action specific toward plus ends. It is approved by United States Food and Drug Administration (USFDA) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. It is also approved as a third line therapy for patients with metastatic breast cancer who have received a prior treatment with anthracycline and taxane in either adjuvant or metastatic setting. It has also undergone investigation in various cancers including non-small cell lung cancer (NSCLC). Areas covered: This review covers eribulin in detail with regards to pharmacodynamics, mechanism of action, pharmacokinetics, published phase I studies along with special focus on phase II and III studies of eribulin in NSCLC. Expert opinion: Eribulin is a potent chemotherapeutic agent with acceptable and easily manageable toxicity profile. It has shown activity in NSCLC. However, the management of NSCLC is undergoing rapid evolution with introduction of newer immune mediated and targeted agents. The way to move forward is to combine eribulin with novel immune checkpoint inhibitors, targeted agents and chemotherapies in appropriate line of therapy.

Original languageEnglish (US)
Pages (from-to)495-508
Number of pages14
JournalExpert Opinion on Investigational Drugs
Volume26
Issue number4
DOIs
StatePublished - Apr 3 2017

Fingerprint

eribulin
Non-Small Cell Lung Carcinoma
Anthracyclines
Liposarcoma
Expert Testimony
United States Food and Drug Administration
Therapeutics
Ketones
Microtubules
Pharmacokinetics
Breast Neoplasms
Drug Therapy

Keywords

  • E7389
  • Eribulin
  • Halaven
  • microtubule inhibitor
  • NSCLC

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Eribulin in non-small cell lung cancer : challenges and potential strategies. / Swami, Umang; Shah, Umang; Goel, Sanjay.

In: Expert Opinion on Investigational Drugs, Vol. 26, No. 4, 03.04.2017, p. 495-508.

Research output: Contribution to journalArticle

@article{7d10c5d8e1bf41f4a4c9616bbb54b67f,
title = "Eribulin in non-small cell lung cancer: challenges and potential strategies",
abstract = "Introduction: Eribulin is a non-taxane, macrocyclic, synthetic, ketone analog of halichondrin B with a microtubule inhibitory action specific toward plus ends. It is approved by United States Food and Drug Administration (USFDA) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. It is also approved as a third line therapy for patients with metastatic breast cancer who have received a prior treatment with anthracycline and taxane in either adjuvant or metastatic setting. It has also undergone investigation in various cancers including non-small cell lung cancer (NSCLC). Areas covered: This review covers eribulin in detail with regards to pharmacodynamics, mechanism of action, pharmacokinetics, published phase I studies along with special focus on phase II and III studies of eribulin in NSCLC. Expert opinion: Eribulin is a potent chemotherapeutic agent with acceptable and easily manageable toxicity profile. It has shown activity in NSCLC. However, the management of NSCLC is undergoing rapid evolution with introduction of newer immune mediated and targeted agents. The way to move forward is to combine eribulin with novel immune checkpoint inhibitors, targeted agents and chemotherapies in appropriate line of therapy.",
keywords = "E7389, Eribulin, Halaven, microtubule inhibitor, NSCLC",
author = "Umang Swami and Umang Shah and Sanjay Goel",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/13543784.2017.1292250",
language = "English (US)",
volume = "26",
pages = "495--508",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Eribulin in non-small cell lung cancer

T2 - challenges and potential strategies

AU - Swami, Umang

AU - Shah, Umang

AU - Goel, Sanjay

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Introduction: Eribulin is a non-taxane, macrocyclic, synthetic, ketone analog of halichondrin B with a microtubule inhibitory action specific toward plus ends. It is approved by United States Food and Drug Administration (USFDA) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. It is also approved as a third line therapy for patients with metastatic breast cancer who have received a prior treatment with anthracycline and taxane in either adjuvant or metastatic setting. It has also undergone investigation in various cancers including non-small cell lung cancer (NSCLC). Areas covered: This review covers eribulin in detail with regards to pharmacodynamics, mechanism of action, pharmacokinetics, published phase I studies along with special focus on phase II and III studies of eribulin in NSCLC. Expert opinion: Eribulin is a potent chemotherapeutic agent with acceptable and easily manageable toxicity profile. It has shown activity in NSCLC. However, the management of NSCLC is undergoing rapid evolution with introduction of newer immune mediated and targeted agents. The way to move forward is to combine eribulin with novel immune checkpoint inhibitors, targeted agents and chemotherapies in appropriate line of therapy.

AB - Introduction: Eribulin is a non-taxane, macrocyclic, synthetic, ketone analog of halichondrin B with a microtubule inhibitory action specific toward plus ends. It is approved by United States Food and Drug Administration (USFDA) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. It is also approved as a third line therapy for patients with metastatic breast cancer who have received a prior treatment with anthracycline and taxane in either adjuvant or metastatic setting. It has also undergone investigation in various cancers including non-small cell lung cancer (NSCLC). Areas covered: This review covers eribulin in detail with regards to pharmacodynamics, mechanism of action, pharmacokinetics, published phase I studies along with special focus on phase II and III studies of eribulin in NSCLC. Expert opinion: Eribulin is a potent chemotherapeutic agent with acceptable and easily manageable toxicity profile. It has shown activity in NSCLC. However, the management of NSCLC is undergoing rapid evolution with introduction of newer immune mediated and targeted agents. The way to move forward is to combine eribulin with novel immune checkpoint inhibitors, targeted agents and chemotherapies in appropriate line of therapy.

KW - E7389

KW - Eribulin

KW - Halaven

KW - microtubule inhibitor

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=85013436967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013436967&partnerID=8YFLogxK

U2 - 10.1080/13543784.2017.1292250

DO - 10.1080/13543784.2017.1292250

M3 - Article

VL - 26

SP - 495

EP - 508

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 4

ER -